-transparent.png){kind=logo}
A series of 4-amino[1,2,4]triazolo[4,3-a]quinoxalines has been prepared. Many compounds from this class reduce immobility in Porsolt's behavioral despair model in rats upon acute administration and may therefore have therapeutic potential as novel and rapid acting antidepressant agents. Optimal activity in this test is associated with hydrogen, CF3, or small alkyl groups in the 1-position, with NH2, NH-acetyl, or amines substituted with small alkyl groups in the 4-position, and with hydrogen or 8-halogen substituents in the aromatic ring. Furthermore, many of these 4-amino[1,2,4]triazolo[4,3-a]quinoxalines bind avidly, and in some cases very selectively, to adenosine A1 and A2 receptors. A1 affinity of these compounds was measured by their inhibition of tritiated CHA (N6-cyclohexyladenosine) binding in rat cerebral cortex membranes and A2 affinity by their inhibition of tritiated NECA (5'-(N-ethylcarbamoyl)adenosine) binding to rat striatal homogenate in the presence of cold N6-cyclopentyladenosine. Structure-activity relationship (SAR) studies show that best A1 affinity is associated with ethyl, CF3, or C2F5 in the 1-position, NH-iPr or NH-cycloalkyl in the 4-position, and with an 8-chloro substituent. Affinity at the A2 receptor is mostly dependent on the presence of an NH2 group in the 4-position and is enhanced by phenyl, CF3, or ethyl in the 1-position. The most selective A1 ligand by a factor of greater than 3000 is 121 (CP-68,247; 8-chloro-4-(cyclohexyl-amino)-1- (trifluoromethyl)[1,2,4]triazolo[4,3-a]quinoxaline) with an IC50 of 28 nM at the A1 receptor. The most potent A2 ligand is 128 (CP-66,713; 4-amino-8-chloro-1- phenyl[1,2,4]triazolo[4,3-a]quinoxaline) with an IC50 of 21 nM at the A2 receptor and a 13-fold selectivity for this receptor. Representatives from this series appear to act as antagonists at both A1 and A2 receptors since they antagonize the inhibiting action of CHA on norepinephrine-stimulated cAMP formation in fat cells and they decrease cAMP accumulation induced by adenosine in limbic forebrain slices. Thus certain members of this 4-amino[1,2,4]triazolo[4,3-a]quinoxaline series are among the most potent and A1 or A2 selective non-xanthine adenosine antagonists known.
R Sarges, and
H R Howard, and
R G Browne, and
L A Lebel, and
P A Seymour, and
B K Koe
May 1988,
Journal of medicinal chemistry,
R Sarges, and
H R Howard, and
R G Browne, and
L A Lebel, and
P A Seymour, and
B K Koe
April 2011,
Bioorganic & medicinal chemistry letters,
R Sarges, and
H R Howard, and
R G Browne, and
L A Lebel, and
P A Seymour, and
B K Koe
December 2003,
Bioorganic & medicinal chemistry,
R Sarges, and
H R Howard, and
R G Browne, and
L A Lebel, and
P A Seymour, and
B K Koe
December 1997,
Archiv der Pharmazie,
R Sarges, and
H R Howard, and
R G Browne, and
L A Lebel, and
P A Seymour, and
B K Koe
May 1998,
Archiv der Pharmazie,
R Sarges, and
H R Howard, and
R G Browne, and
L A Lebel, and
P A Seymour, and
B K Koe
March 1996,
Journal of medicinal chemistry,
R Sarges, and
H R Howard, and
R G Browne, and
L A Lebel, and
P A Seymour, and
B K Koe
March 2000,
Journal of medicinal chemistry,
R Sarges, and
H R Howard, and
R G Browne, and
L A Lebel, and
P A Seymour, and
B K Koe
August 1997,
Die Pharmazie,
R Sarges, and
H R Howard, and
R G Browne, and
L A Lebel, and
P A Seymour, and
B K Koe
February 2009,
Bioorganic & medicinal chemistry letters,
R Sarges, and
H R Howard, and
R G Browne, and
L A Lebel, and
P A Seymour, and
B K Koe
November 1999,
Journal of medicinal chemistry,
